Back

Efficacy and safety of prolonged rivaroxaban treatment for high-bleeding risk cancer patients with acute low-risk pulmonary embolism: a post-hoc subgroup analysis of the ONCO PE trial

31 August 2025 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pulmonary embolism: general Venous Thromboembolism ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Tomoyuki Nagai

Kyoto Prefectural University of Medicine, Kyoto (Japan)

6 More presentations in this session

Presentation thumbnail
Gender disparities in high-risk pulmonary embolism: a nationwide analysis of management strategies and clinical outcomes
Doctor A. Folman (Hadera, IL)
Abstract Slides Video
Presentation thumbnail
Pandemic-era shifts in acute pulmonary embolism outcomes: national inpatient sample analysis of mortality and resource utilization (2016-2021)
Doctor M. Gatuz (Candon City, PH)
Abstract Slides Video
Presentation thumbnail
A meta-analysis of catheter-directed thrombolysis versus standard anticoagulation among patients with intermediate high risk pulmonary embolism
Doctor M. Apistar (Cebu, PH)
Abstract Slides Video
Presentation thumbnail
Burden and long-term impact of pulmonary embolism on health-related quality of life: a matched cohort study
Mr I. Farmakis (Munich, DE)
Abstract Slides Video
Presentation thumbnail
High-sensitivity troponin-t concentrations and early risk of myocardial infarction in patients with acute pulmonary embolism
Doctor J. Frary (Hellerup, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary embolism: general

The Event

Event poster

ESC Congress 2025

31 August 2025 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Net clinical benefit of 18-month over 6-month rivaroxaban in patients with cancer and acute low-risk pulmonary embolism: Insight from the ONCO PE trial
thumbnail
Congress Presentation
Clinical outcomes of half-dose extended anticoagulation in cancer-associated pulmonary thromboembolism: a real-world cohort study
thumbnail
Congress Presentation
Effective venous thromboembolism treatment in high bleeding- risk patients

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources